Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Impact · against what's priced in

Absci receives a significant valuation boost and validation from Eli Lilly's participation in its $100 million equity raise, though this is partially offset by the immediate dilution of 13.5 million new shares. For Eli Lilly, the investment is a minor strategic signal of interest in AI drug discovery with negligible impact on its overall valuation.

ABSI+0.30

No priced-in read yet